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ABSTRACT
Insulin resistance is a major risk factor for patients with type 2 diabetes 
mellitus (T2DM). Telmisartan and valsartan are angiotensin II type I receptor 
blockers (ARBs) that are often used in patients with metabolic syndrome and 
T2DM. This study aimed to compare the effect of valsartan and telmisartan in 
reducing insulin resistance on T2DM with hypertension. Patients of T2DM were 
open-label screened at the Endocrinology Policlinic, Department of Internal 
Medicine, Dr. Sardjito General Hospital, Yogyakarta, and then randomized into 
two groups. The first group received valsartan 80 mg per day up to 160 mg per 
day, the second group received telmisartan 40 mg per day up to 80 mg per day 
in addition with life-style modifying and diabetes therapy. Homeostasis model 
assessment of insulin resistance (HOMA-IR), triglyceride and HDL cholesterol 
levels of patients were measured before and after receiving telmisartan and 
valsartan for 12 weeks. A total of forty-nine outpatients were involved in this 
study comprised of 25 female patients (51%) and 24 male patients (49%) with 
27 patients (55.1%) received telmisartan and 22 patients (44.9%) received 
valsartan as the hypertension therapy. No significantl difference were observed 
between telmisartan group compared with valsartan group in HOMA-IR (14.01 
± 16.39 vs. 5.31 ± 3.51; p=0.053), triglyceride levels (165.71 ± 94.70 vs 144.41 ± 
48.33 mg/dL; p=0.620), HDL-C level (48.57 ± 9.78 vs 49.24 vs 49.24 ± 12.56 mg/dL; 
p=0.999). In conclusion, telmisartan demonstrated no difference compared to 
valsartan in reducing insulin resistance on T2DM patients with hypertension.
ABSTRAK
Resistensi insulin merupakan masalah utama pada penatalaksanaan pasien 
diabetes militus tipe 2 (DMT2). Telmisartan dan valsartan merupakan 
penghambat reseptor angiotensin II tipe I (ARB) yang sering digunakan pada 
pasien sindrom metabolik dan DMT2. Penelitian ini bertujuan membandingan 
efek telmisartan dan valsartan dalam menurunkan resistensi insulin pada 
pasien DMT2 dengan hipertensi. Pasien DMT2 diskrining dengan model 
terbuka di Poloklinik Endokrinologi, Departemen Ilmu Penyakit Dalam, Rumah 
Sakit Umum Pusat Dr. Sardjito, Yogyakarta dan kemudian dibagi secara acak 
menjadi dua kelompok. Kelompok pertama mendapat valsartan 80 mg sampai 
160 mg dan kelompok kedua mendapatkan telmisartan 40 mg sampai 80 mg, 
disamping diet dan terapi diabetes rutin. Nilai HOMA-IR, kadar trigliserid dan 
HDL kolesterol diperiksa sebelum dan sesudah mendapat telmisartan dan 
valsartan selama 12 minggu. Total 49 pasien DMT2 dengan hipertensi terlibat 
dalam penelitian yang terdiri dari 25 pasien wanita (51%) dan 24  pasien laki-
laki (49%) dan 27 pasien (55,1%) menerima telmisartan dan 22 pasien (44,9%) 
menerima valsartan sebagai terapi hipertensinya. Tidak terdapat perbedaan 
bermakna antara kelompok telmisartan dibandingkan dengan kelompok 
valsartan untuk nilai HOMA-IR (14,01 ± 16,39 vs. 5,31 ± 3,51; p=0,053), kadar 
trigliserid (165,71 ± 94,70 vs 144,41 ± 48,33 mg/dL; p=0,620), kadar kolesterol 
HDL (48,57 ± 9,78 vs 49,24 vs 49,24 ± 12,56 mg/dL; p=0,999). Dapat disimpulkan, 
tidak terdapat perbedaan efek antara telmisartan dan valsartan dalam 
menurunkan resistensi insulin pada pasien DMT2 dengan hipertensi.  
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INTRODUCTION
Insulin resistance is a major risk 
factor for type 2 diabetes mellitus 
(T2DM). Insulin resistance contributes 
the development of T2DM through the 
action of attenuating insulin secretion 
and metabolic action.1,2 One of the 
most widely used oral antidiabetic 
agents aimed to increase insulin 
sensitivity is thiazolidinedione group. 
Thiazolidinediones act by activating 
peroxisome proliferator activated 
receptor-γ (PPAR-γ).3
Several studies concerning 
angiotensin II type I receptor blocker 
(ARBs) as hypertension therapy showed 
significant effect on intracellular 
insulin signalling pathway repairment 
and reducing incidence of T2DM. 
Telmisartan has a unique profile 
compared to other ARBs by its selective 
ability to activate PPAR-γ, reducing the 
risk of oedema and heart failure in 
patients with hypertension.4-7 Moreover, 
telmisartan is more effective to reduce 
insulin resistance than valsartan in 
hypertensive patients with metabolic 
syndrome.8 This study aimed to evaluate 
the effect of telmisartan or valsartan in 
reducing of insulin resistance in T2DM 
patients with hypertension. 
MATERIALS AND METHODS
Subjects 
This was open-label, randomization 
clinical study conducted in the Internal 
Medicine Clinic, Dr. Sardjito General 
Hospital, Yogyakarta. Male and female 
patients aged of 35-60 y.o that fulfilled 
the ADA 2010 Diabetes Mellitus criteria 
and JNC VII hypertension criteria, 9 were 
consented to be included to the research 
by signing informed consent form. The 
patients were excluded under certain 
conditions such as 1) kidney failure; 2) 
heart failure; 3) lung failure; 4) patients 
whose blood pressure measurement 
>160/100 mmHg after being treated 
with hypertension therapy; 5) 
pregnant women; 6) smoker; 7) alcohol 
consumer; and 8) patients who received 
corticosteroid therapy.
Protocol of study
Subjects who fulfilled the 
criteria would be measured for waist 
circumference, body weight and height, 
and blood pressure, then randomized 
into 2 groups. The first group was given 
life-modifying therapy, diabetes therapy, 
and telmisartan 40 mg per day up to 80 
mg per day. The second group was given 
life-modifying therapy, diabetes therapy, 
and valsartan 80 mg per day up to 160 mg 
per day. If the patient’s blood pressure 
failed to achieve 130/80 mmHg, patients 
were treated with calcium channel 
blocker (CCB) agents. Insulin as diabetic 
therapy should not be stopped. 
The study was being conducted 
for 12 weeks. Subject’s blood pressure 
was measured for every 2 weeks. The 
parameters were collected, including 
1) metabolic parameters; (2) waist 
circumference; 3) body mass index (BMI); 
4) homeostasis model assessment insulin 
resistance (HOMA IR) index determined 
by fasting insulin level and fasting blood 
glucose level;10 5) triglyceride level; and 
6) HDL cholesterol level.
Statistical analysis
Data were presented as mean ± 
standard deviation (SD). Independent 
samples t-test analysis was used to 
compare the difference between 
means of two independent groups 
with numerical variables (p>0.05) and 
Mann-Whitney U-test was used if the 
means of two independent groups were 
analyzed with non-parametric test 
(p<0.05). Chi square test analysis was 
used to determine whether there was 
a significant difference between two 
groups prescribed with telmisartan and 
valsartan (α =0.05).
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RESULTS
Subjects that enrolled into the 
study were type 2 DM outpatients with 
hypertension who attended routine 
medical care in endocrinology clinic, Dr. 
Sardjito General Hospital, Yogyakarta. A 
total of forty-nine outpatients comprised 
of 25 female patients (51%) and 24 male 
patients (49%) with 27 patients aged 
57.52 ± 5.07 year-old received telmisartan 
as hypertension therapy (55.1%) and 
22 patients aged 56.65 ± 5.07 year-old 
received valsartan as hypertension 
therapy (44.9%). HOMA IR profile were 
not available in all enrolled subjects, 
therefore only 38 enrolled subjects were 
analyzed into the study, 21 patients on 
telmisartan therapy and 17 patients on 
valsartan therapy. Means of BMI and 
waist circumference before and after 
12 weeks treatment with telmisartan or 
valsartan is presented in TABLE 1.
TABLE 2 shows the means of 
homeostasis model assessment insulin 
resistance (HOMA-IR), triglyceride, and 
HDL cholesterol level after 12 weeks 
treatment with telmisartan or valsartan.
TABLE 1. Means values ± SD of BMI and waist circumference before and after 12 weeks 











BMI 28.25 ± 2.96 27.88 ± 3.21 0.690 28.12 ± 3.15 27.11 ± 3.07 0.694
Waist circumference 97.60 ± 6.96 96.47 ± 8.35 0.540 96.10 ± 7.30 97.56 ± 7.17 0.541
TABLE 2. Means values ± SD of homeostasis model assessment insulin 
resistance (HOMA-IR), triglyceride, and HDL cholesterol level 




HOMA-IR 14.01 ± 16.39 5.31 ± 3.51
0.053
Trans HOMA-IR 0.90 ± 0.48 0.64 ±  0.27
Triglyceride level 165.71 ± 94.702 144.41 ± 48.33
0.620
Trans triglyceride level 2.11 ± 0.21 0.14 ± 0.14
HDL cholesterol level 48.57 ± 9.78 49.24 ± 12.56
0.999
Trans HDL cholesterol level 1.68 ± 0.08 1.68 ± 0.11
DISCUSSION
Mean values of BMI and waist 
circumference evaluation as parameters 
for obesity did not show different results 
after patients received insulin and either 
telmisartan or valsartan at the end of the 
study. It showed that obesity as causative 
factor of insulin resistance showed no 
difference. Obesity is an essential factor 
for insulin resistance. Adipose tissue, 
alongside its function as source of energy 
preservation, is considered an endocrine 
organ that influences glucose metabolism 
by releasing adipokines, free fatty acids 
(FFA), adipokines, leptin, and resistin.11 
Insulin resistance in obesity is associated 
with impaired inhibition of lipolysis by 
insulin, resulting in increased release 
of FFA and glycerol. The release of FFA 
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solicited insulin resistance in muscle 
and adipose tissue by impairing GLUT4 
receptor translocation and fusion in cell 
membrane. Visceral adipose tissue is 
considered more lipolytically active on a 
per unit weight basis than subcutaneous 
fat.12 Abdominal obesity increases 
the likelihood of FFA circulation as 
it can directly enter the liver via the 
portal circulation, which increases 
lipid synthesis and gluconeogenesis by 
the increased level of FFA, eventually 
causing insulin resistance.13,14
Lipid profile displayed by patients 
in this study also did not show any 
significant difference accordant to the 
level of insulin resistance between two 
groups that also did not show significant 
difference. Dyslipidemia is precipitated 
by insulin resistance by increasingly 
active lipolysis mechanisms in adipose 
tissue. The increased production of FFA 
resulted in generation of VLDL in liver, a 
major type of lipoprotein with high degree 
of lipid density, which initially converted 
to LDL cholesterol. Subsequently, LDL 
cholesterol converted to small dense 
LDL cholesterol (sdLDL), a distinct LDL 
cholesterol subclass which very dense 
in triglycerides in smaller particles. 
HDL cholesterol, which also contains 
abundant amounts of triglycerides, is 
transferred to Apo-B and excreted in the 
renal system, thus HDL cholesterol level 
in circulation will be lowered.15
The results of this study were 
different from previous meta-analysis 
study comparing telmisartan with other 
ARBs agents, which resulted in blood 
glucose level and insulin sensitivity 
improvement on subjects who received 
telmisartan.7 Another study to compare 
the effects of telmisartan and valsartan 
in insulin resistance reduction by 
evaluation of  HOMA-IR demonstrated 
the improvement of insulin sensitivity 
within 4 weeks in patients with metabolic 
syndrome, with means value of subject’s 
age study 65 year-old.8 This study 
showed a different outcome compared 
to the previous studies in which the 
subjects are T2DM patients treated with 
insulin with weight gain as the side 
effect that eventually worsens insulin 
resistance.  Meanwhile, in this study, 
the patient’s mean age was relatively 
younger, 56 year-old, which may be 
one of the determinants as to why the 
studies demonstrated different results. 
Diet adjustment, physical activities, and 
patient’s compliance also contributed to 
confounding factors that may influence 
this study’s result, based on the 12 weeks 
duration of the study.
A study carried out by Derosa et al.16 
showed telmisartan prescribed for 12 
months also improved insulin resistance 
with addition of rosiglitazone therapy 
which amplified the increase in insulin 
resistance. Compared to this shorter 
study period of only 12 weeks, the effect 
of improving insulin sensitivity had not 
been seen and the experiment did not 
involve other drugs that can amplify the 
insulin sensitivity.
This study’s result is also similar to 
other studies investigating the effect 
of telmisartan on insulin resistance in 
patients with hypertension and T2DM 
on improving insulin sensitivity, which 
is not significant.17-19 This evidence 
suggests that telmisartan is not always 
effective in improving insulin resistance, 
most likely influenced by unknown 
factors. Although we failed to obtain 
data suggesting improvement in insulin 
resistance by telmisartan, it could be 
considered a variation in study results 
that would determine the drug’s efficacy 
in clinical setting.
The main limitations of this study are 
the open label design, the small number 
of participants, and the relatively short 
treatment period. A double blind study 
with a larger patient population and 
a longer treatment period is needed 
to investigated to determine the effect 
of telmisartan on insulin resistance in 
patients with hypertension and Ttype 
2DM diabetes mellitus with insulin 
therapy.
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CONCLUSION
This study demonstrates no 
significant difference in insulin 
resistance reduction in hypertensive 
T2DM patients with insulin therapy 
who received telmisartan compared to 
who received valsartan after 12 weeks 
treatment.
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